Corcept (CORT) director Wilson reports 5,000-share stock gift via trust

Rhea-AI Filing Summary

Corcept Therapeutics director James N. Wilson reported a bona fide gift of 5,000 shares of Common Stock on April 6, 2026. The transfer was made by the James N. Wilson and Pamela D. Wilson Trust and is classified as a non-market, no‑price gift disposition.

Following the gift, the trust held 1,097,532 shares indirectly, while the James and Pamela Wilson Family Partners entity held 901,067 shares, and each of the 2025 Grantor Retained Annuity Trusts held 200,000 shares. Wilson has voting power under voting agreements but disclaims beneficial ownership beyond his pecuniary interest.

Insider Trade Summary

5,000 shares gifted

Mixed 4 txns

Insider WILSON JAMES N

Role Director

Type	Security	Shares	Price	Value
Gift	Common Stock	5,000	$0.00	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,097,532 shares (Indirect, James N. Wilson and Pamela D. Wilson Trust)

Footnotes (1)

1. [object Object]

Key Figures

Gifted shares: 5,000 shares Trust holdings after gift: 1,097,532 shares Family partnership holdings: 901,067 shares +2 more

5 metrics

Gifted shares 5,000 shares Bona fide gift on April 6, 2026

Trust holdings after gift 1,097,532 shares James N. and Pamela D. Wilson Trust, April 6, 2026

Family partnership holdings 901,067 shares James and Pamela Wilson Family Partners, April 6, 2026

Grantor Retained Annuity Trust holdings 200,000 shares Each 2025 Grantor Retained Annuity Trust, April 6, 2026

Gift transaction price $0.0000 per share Bona fide gift, non-market transfer

Key Terms

bona fide gift, Grantor Retained Annuity Trust, beneficial ownership, voting agreements

4 terms

bona fide gift financial

"reported a bona fide gift of 5,000 shares of Common Stock"

Grantor Retained Annuity Trust financial

"each of the 2025 Grantor Retained Annuity Trusts held 200,000 shares"

A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.

beneficial ownership financial

"disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

voting agreements financial

"has voting power over the shares held ... pursuant to voting agreements"

A voting agreement is a legally binding deal where shareholders promise to cast their votes the same way on corporate matters, such as choosing directors or approving big transactions. Think of it like a neighborhood group agreeing to support the same candidate so they can decide how the block is run; for investors, these pacts can change who controls a company, influence strategy and risk, and affect the value and liquidity of shares.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WILSON JAMES N

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CALIFORNIA 94065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/06/2026		G		5,000	D	$0.00	1,097,532	I	James N. Wilson and Pamela D. Wilson Trust(1)
Common Stock								901,067	I	James and Pamela Wilson Family Partners(1)
Common Stock								200,000	I	James N. Wilson 2025 Grantor Retained Annuity Trust.
Common Stock								200,000	I	Pamela D. Wilson 2025 Grantor Retained Annuity Trust.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for James N. Wilson	04/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Corcept Therapeutics (CORT) director James N. Wilson report?

Director James N. Wilson reported a bona fide gift of 5,000 shares of Corcept Therapeutics Common Stock on April 6, 2026. The transfer was made at no price by the James N. Wilson and Pamela D. Wilson Trust and is a non-market disposition.

How many Corcept Therapeutics (CORT) shares did the Wilson trust hold after the reported gift?

After the gift transaction, the James N. Wilson and Pamela D. Wilson Trust held 1,097,532 Corcept Therapeutics shares indirectly. This figure reflects the trust’s position following the 5,000‑share bona fide gift reported for April 6, 2026, as shown in the Form 4 data.

What other indirect holdings related to James N. Wilson are disclosed for Corcept Therapeutics (CORT)?

Indirect holdings include 901,067 shares held by James and Pamela Wilson Family Partners and 200,000 shares in each of two 2025 Grantor Retained Annuity Trusts. These positions are reported as indirect ownership entries dated April 6, 2026, alongside the trust’s larger holding.

Does James N. Wilson claim full beneficial ownership of the reported Corcept Therapeutics (CORT) shares?

No. A footnote states that Wilson has voting power under voting agreements over shares held by the trust and family partnership but disclaims beneficial ownership, except to the extent of his pecuniary interest in those entities. This limits how much of the position is attributable to him economically.

Was the Corcept Therapeutics (CORT) insider transaction a market sale or purchase?

The filing shows a bona fide gift of 5,000 shares, not a market sale or purchase. The transaction code is G, indicating a gift transfer at a reported price per share of 0.0000, so it does not reflect an open-market trade in Corcept shares.